| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Chief Development Officer | Officer Level 14 | EVP, Chief Development Offc +2 more
1 company
Richard S Geary is EVP, Chief Development Officer at IONS. Richard S Geary's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.4M at current prices.
Historically, Richard S Geary's trades have earned a middling insider score of 66/100 across 19 rated trades. Over a 12-month horizon, 64.7% of those trades were profitable, with an average 12-month return of +1.2%.
The IONS filings lean toward selling, a net 342,724 shares.
Richard S Geary has 48 Form 4 filings on record from January 2019 to November 2025, all as EVP, Chief Development Officer at Ionis Pharmaceuticals (IONS), 2019–2025.
The 101 reported transactions were 35 open-market sales, 28 option exercises, 18 option or other derivative awards and 13 other transactions, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 22 sales worth about $22.7M.
The largest open-market sale was 90,929 shares of IONS at an average $75.11 on November 3, 2025, about $6.8M. Twelve months later IONS was down 40%.
9 of the 13 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 4 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 6, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Development Officer | Sale+OE10b5-1 | 34,639 | $75.69 | $2,621,815.84 | -36.7% | +14.7% | - | |
| Nov 3, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Development Officer | Sale+OE10b5-1 | 90,929 | $75.11 | $6,829,431.39 | -60.4% | +12.8% | -39.7% | |
| Sep 30, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Development Officer | Sale+OE10b5-1 | 57,900 | $65.24 | $3,777,668.13 | -42.1% | +22.3% | -31.7% | |
| Sep 2, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Development Officer | Sell10b5-1 | 10,000 | $50.37 | $503,671.00 | -11.2% | +42.6% | +6.7% | |
| Aug 5, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Development Officer | Sell10b5-1 | 10,000 | $42.86 | $428,593.00 | -10.1% | +71.1% | +25.9% | |
| Jan 31, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Development Officer | Sell | 1,406 | $32.40 | $45,561.29 | -1.4% | -0.6% | +159.2% | |
| Jan 16, 2025 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Development Officer | Sale+OE | 7,072 | $32.86 | $232,407.14 | -6.8% | -12.2% | +136.5% | |
| Aug 29, 2024 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Development Officer | Sell10b5-1 | 651 | $49.40 | $32,158.73 | -0.8% | -28.1% | -14.6% | |
| Aug 5, 2024 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Development Officer | Sell10b5-1 | 2,430 | $48.00 | $116,640.00 | -2.8% | -18.2% | -8.4% | |
| Feb 2, 2024 | IONS Ionis Pharmaceuticals Inc | EVP, Chief Development Officer | Sell | 1,961 | $50.04 | $98,134.91 | -2.2% | -13.4% | -35.9% |